Hospital
Alaska Native Tribal Health Consortium
Alaska Native Tribal Health Consortium was paid $397.15M by Medicaid between Jan 2018 and Dec 2024, across 506 billing codes. Its largest line is 99211, Office or other outpatient visit for the evaluation and management of an established patient, minimal severity — 19% of everything it billed.
33Billing provider infoALASKA NATIVE TRIBAL HEALTH CONSORTIUM
ANCHORAGE, AK 99508
ANCHORAGE, AK 99508
33aNPI1437368891assigned 05/22/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$397.15M
24GClaims2,150,032
24DCodes billed506
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Alaska
Rank by total paid#1 of 10
Median peer was paid$30.98M
This provider vs. median13×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 319,246 | $45.84M | |
| 2019 | 337,332 | $50.34M | |
| 2020 | 272,797 | $54.68M | |
| 2021 | 321,518 | $70.80M | |
| 2022 | 309,856 | $67.40M | |
| 2023 | 304,010 | $51.50M | |
| 2024incomplete | 285,273 | $56.58M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 19% | 256,406 | 189,437 | $73.54M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 16% | 119,847 | 101,255 | $64.64M |
| 80053 | Comprehensive metabolic panel | 5.1% | 67,812 | 58,606 | $20.09M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 4.8% | 55,096 | 44,024 | $19.00M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 4.5% | 86,296 | 76,801 | $17.97M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.4% | 20,642 | 18,482 | $9.56M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.0% | 18,009 | 16,933 | $8.01M |
| 87081 | 2.0% | 13,710 | 13,372 | $7.85M | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 1.9% | 36,078 | 35,248 | $7.44M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.9% | 54,510 | 51,597 | $7.36M |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.8% | 27,175 | 25,145 | $6.98M |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.6% | 22,813 | 22,512 | $6.54M |
494 more codes
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.6% | 17,652 | $6.22M |
| 83540 | 1.5% | 11,455 | $5.97M | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.4% | 12,673 | $5.65M |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.4% | 10,556 | $5.49M |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.2% | 10,860 | $4.58M |
| 99284 | Emergency room visit (serious) | 1.1% | 53,861 | $4.37M |
| 84443 | Thyroid stimulating hormone (TSH) | 1.0% | 37,712 | $3.98M |
| 86900 | <1% | 7,946 | $3.92M | |
| 36415 | Collection of venous blood by venipuncture | <1% | 35,138 | $3.12M |
| 80074 | <1% | 8,114 | $3.10M | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 6,054 | $3.04M |
| 71046 | Radiologic examination, chest; 2 views | <1% | 20,417 | $2.77M |
| 87077 | <1% | 5,012 | $2.59M | |
| 87631 | <1% | 4,716 | $2.43M | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 4,427 | $2.40M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 10,145 | $2.39M |
| 87070 | <1% | 6,632 | $2.37M | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 6,997 | $2.32M |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 3,471 | $2.25M |
| 81001 | <1% | 37,080 | $2.07M | |
| 84439 | <1% | 9,013 | $2.05M | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 3,673 | $1.79M |
| 99285 | Emergency room visit (most serious) | <1% | 29,864 | $1.78M |
| 87522 | Neg quan hep c or qual rna | <1% | 3,819 | $1.78M |
| 87210 | <1% | 9,444 | $1.72M | |
| 82043 | <1% | 4,181 | $1.63M | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,946 | $1.62M |
| 84702 | <1% | 5,868 | $1.62M | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 5,538 | $1.52M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 3,879 | $1.44M |
| 73610 | <1% | 3,900 | $1.28M | |
| 80076 | <1% | 3,538 | $1.26M | |
| 59025 | Fetal non-stress test | <1% | 7,976 | $1.25M |
| 73130 | <1% | 3,452 | $1.19M | |
| 92557 | <1% | 3,060 | $1.18M | |
| 80306 | <1% | 14,539 | $1.18M | |
| 81025 | <1% | 19,843 | $1.13M | |
| 76818 | <1% | 1,810 | $1.11M | |
| 73630 | <1% | 3,789 | $1.10M | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 7,129 | $1.08M |
| 73140 | <1% | 2,274 | $1.05M | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 73,226 | $1.04M |
| 82570 | <1% | 8,810 | $1.03M | |
| 85610 | <1% | 12,635 | $1.02M | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 1,588 | $991K |
| 73030 | <1% | 2,919 | $987K | |
| 73110 | <1% | 2,827 | $947K | |
| 82274 | <1% | 2,240 | $945K | |
| 82785 | <1% | 1,432 | $927K | |
| 81003 | <1% | 13,416 | $868K | |
| 86780 | <1% | 34,850 | $841K | |
| 97161 | <1% | 2,563 | $830K | |
| 82105 | <1% | 4,551 | $816K | |
| 73562 | <1% | 2,622 | $796K | |
| J3490 | Unclassified drugs | <1% | 5,851 | $775K |
| 80069 | <1% | 1,701 | $709K | |
| 86038 | <1% | 1,779 | $699K | |
| A4565 | Slings | <1% | 1,299 | $697K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,848 | $663K |
| 82607 | <1% | 6,292 | $652K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 6,074 | $621K |
| 73564 | <1% | 1,407 | $607K | |
| 20610 | <1% | 1,197 | $606K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,737 | $603K |
| 82962 | <1% | 2,058 | $603K | |
| 80061 | Lipid panel | <1% | 9,110 | $595K |
| 83880 | <1% | 10,706 | $583K | |
| 82728 | <1% | 12,239 | $581K | |
| 73590 | <1% | 1,739 | $575K | |
| 87481 | <1% | 1,419 | $534K | |
| 72100 | <1% | 1,491 | $519K | |
| 84153 | <1% | 2,005 | $511K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,115 | $482K |
| 92567 | <1% | 5,968 | $465K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,865 | $452K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,404 | $451K |
| 73502 | <1% | 1,198 | $451K | |
| 73090 | <1% | 1,205 | $422K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 762 | $421K |
| 12001 | <1% | 1,028 | $417K | |
| 86141 | <1% | 7,494 | $406K | |
| 73080 | <1% | 1,094 | $395K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,528 | $383K |
| 88142 | <1% | 7,591 | $377K | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 805 | $364K |
| 71250 | <1% | 693 | $363K | |
| 81002 | <1% | 751 | $360K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 3,404 | $360K |
| 93296 | <1% | 610 | $353K | |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 711 | $330K |
| 82239 | <1% | 710 | $322K | |
| 76642 | <1% | 674 | $319K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 9,112 | $308K |
| 76775 | <1% | 689 | $307K | |
| 70486 | <1% | 1,996 | $304K | |
| 92015 | Determination of refractive state | <1% | 1,523 | $298K |
| 74018 | <1% | 838 | $280K | |
| 84703 | <1% | 6,968 | $275K | |
| 17110 | <1% | 557 | $268K | |
| 92555 | <1% | 896 | $265K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,377 | $261K |
| 83655 | <1% | 416 | $261K | |
| 69210 | <1% | 682 | $261K | |
| 93225 | <1% | 605 | $255K | |
| 84156 | <1% | 5,190 | $252K | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 562 | $252K |
| 91200 | <1% | 472 | $239K | |
| 31575 | <1% | 486 | $227K | |
| 83001 | <1% | 1,212 | $224K | |
| 87486 | <1% | 544 | $220K | |
| 20552 | <1% | 426 | $220K | |
| 92002 | <1% | 558 | $220K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 28,213 | $217K |
| 86480 | <1% | 1,188 | $211K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 828 | $203K |
| 86803 | <1% | 14,727 | $198K | |
| 84146 | <1% | 1,275 | $194K | |
| 92552 | <1% | 456 | $191K | |
| 71101 | <1% | 426 | $184K | |
| 92504 | <1% | 2,391 | $179K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 257 | $172K |
| 96367 | <1% | 2,024 | $169K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 6,755 | $168K |
| 97162 | <1% | 682 | $165K | |
| 84030 | <1% | 301 | $159K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 48,594 | $159K |
| 73560 | <1% | 448 | $155K | |
| 71045 | Radiologic examination, chest; single view | <1% | 3,724 | $154K |
| V5011 | Fitting/orientation/checking of hearing aid | <1% | 530 | $152K |
| 82784 | <1% | 972 | $151K | |
| 82247 | <1% | 323 | $149K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 1,125 | $138K |
| 20611 | <1% | 302 | $131K | |
| 10060 | <1% | 788 | $130K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 420 | $130K |
| 31231 | <1% | 303 | $130K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 327 | $129K |
| 85027 | <1% | 4,965 | $129K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,400 | $127K |
| 86704 | <1% | 3,222 | $126K | |
| 73000 | <1% | 295 | $121K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 548 | $118K |
| 72110 | <1% | 209 | $116K | |
| 96368 | <1% | 675 | $116K | |
| 82330 | <1% | 1,331 | $116K | |
| L3260 | Surgical boot/shoe, each | <1% | 209 | $115K |
| 84403 | <1% | 885 | $114K | |
| 95886 | <1% | 240 | $114K | |
| 80164 | <1% | 364 | $110K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,048 | $110K |
| 74230 | <1% | 170 | $110K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,607 | $107K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,921 | $106K |
| L3908 | Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf | <1% | 181 | $104K |
| 87420 | <1% | 1,427 | $98K | |
| 72040 | <1% | 213 | $98K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 364 | $96K |
| 86592 | <1% | 1,273 | $94K | |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 218 | $93K |
| 51798 | <1% | 473 | $90K | |
| 84484 | <1% | 12,608 | $88K | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 193 | $85K |
| 86593 | <1% | 1,005 | $84K | |
| 12011 | <1% | 223 | $79K | |
| 93971 | <1% | 266 | $78K | |
| 80171 | <1% | 151 | $75K | |
| 83735 | <1% | 14,990 | $74K | |
| 86200 | <1% | 749 | $74K | |
| G0378 | Hospital observation service, per hour | <1% | 129 | $73K |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 861 | $71K |
| 92060 | <1% | 810 | $69K | |
| 93351 | <1% | 174 | $69K | |
| 97165 | <1% | 314 | $69K | |
| 87040 | <1% | 2,901 | $67K | |
| 82670 | <1% | 286 | $65K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 17,391 | $65K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,389 | $64K |
| L4350 | Ankle control orthosis, stirrup style, rigid, includes any type interface (e.g., pneumatic, gel), prefabricated, off-the-shelf | <1% | 112 | $63K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 4,556 | $62K |
| 83690 | <1% | 19,496 | $62K | |
| 29125 | <1% | 706 | $61K | |
| 85379 | <1% | 1,966 | $60K | |
| 93246 | <1% | 121 | $57K | |
| 86431 | <1% | 1,741 | $54K | |
| 76830 | Ultrasound, transvaginal | <1% | 513 | $54K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 100 | $51K |
| 82378 | <1% | 1,298 | $50K | |
| 95819 | <1% | 104 | $50K | |
| 82565 | <1% | 756 | $50K | |
| 76536 | <1% | 85 | $50K | |
| 92134 | <1% | 772 | $48K | |
| 83970 | <1% | 1,454 | $47K | |
| 92591 | <1% | 309 | $43K | |
| 82533 | <1% | 198 | $42K | |
| 76000 | <1% | 167 | $41K | |
| L3040 | Foot, arch support, removable, premolded, longitudinal, each | <1% | 93 | $41K |
| 86706 | <1% | 3,464 | $39K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 980 | $39K |
| 83605 | <1% | 9,437 | $39K | |
| 87015 | <1% | 197 | $38K | |
| 82947 | <1% | 1,146 | $38K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 210 | $38K |
| 84145 | <1% | 1,918 | $38K | |
| 82951 | <1% | 72 | $37K | |
| 80051 | <1% | 189 | $36K | |
| 92593 | <1% | 137 | $36K | |
| 94060 | <1% | 74 | $36K | |
| 77077 | <1% | 137 | $34K | |
| 74022 | <1% | 369 | $33K | |
| 83516 | <1% | 523 | $33K | |
| 72170 | <1% | 107 | $33K | |
| 82746 | <1% | 3,363 | $32K | |
| 11900 | <1% | 316 | $32K | |
| 88304 | <1% | 191 | $31K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 20,000 | $31K |
| 82550 | <1% | 1,957 | $30K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,349 | $29K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 104 | $29K |
| 73070 | <1% | 77 | $29K | |
| 81015 | <1% | 460 | $29K | |
| 64615 | <1% | 56 | $28K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,229 | $28K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,073 | $27K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 658 | $27K |
| 87536 | <1% | 223 | $27K | |
| L1810 | Knee orthosis, elastic with joints, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise | <1% | 45 | $24K |
| 86003 | <1% | 1,637 | $23K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 109 | $23K |
| 73120 | <1% | 139 | $23K | |
| 77065 | Tomosynthesis, mammo | <1% | 108 | $23K |
| 92553 | <1% | 60 | $23K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 13,444 | $22K |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 406 | $22K |
| 90715 | <1% | 2,360 | $21K | |
| 36416 | <1% | 538 | $21K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 5,840 | $21K |
| 92556 | <1% | 337 | $20K | |
| 93308 | <1% | 117 | $20K | |
| 86695 | <1% | 416 | $20K | |
| 93976 | <1% | 264 | $20K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,826 | $19K |
| 76801 | <1% | 501 | $18K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 279 | $18K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 7,741 | $18K |
| 87255 | <1% | 77 | $17K | |
| 90686 | <1% | 662 | $17K | |
| 85652 | <1% | 4,979 | $17K | |
| 86762 | <1% | 3,857 | $16K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 219 | $16K |
| V5014 | Repair/modification of a hearing aid | <1% | 220 | $16K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 34 | $15K |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 86 | $15K |
| 87517 | <1% | 647 | $15K | |
| 86580 | <1% | 38 | $15K | |
| L3334 | Lift, elevation, heel, per inch | <1% | 53 | $14K |
| 73600 | <1% | 45 | $14K | |
| 77061 | <1% | 25 | $14K | |
| 92579 | <1% | 725 | $14K | |
| 52000 | <1% | 37 | $14K | |
| 73660 | <1% | 42 | $13K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 716 | $12K |
| 10061 | <1% | 127 | $12K | |
| 96411 | <1% | 54 | $12K | |
| 20680 | <1% | 14 | $12K | |
| 87340 | <1% | 8,570 | $12K | |
| 77066 | Tomosynthesis, mammo | <1% | 53 | $11K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 3,457 | $11K |
| 93242 | <1% | 26 | $11K | |
| 73620 | <1% | 87 | $11K | |
| 83013 | <1% | 14 | $11K | |
| 83615 | <1% | 1,116 | $11K | |
| 82542 | <1% | 1,319 | $11K | |
| 92133 | <1% | 52 | $11K | |
| 12002 | <1% | 39 | $10K | |
| 73700 | <1% | 25 | $10K | |
| 95812 | <1% | 12 | $9K | |
| 77062 | <1% | 15 | $9K | |
| 73552 | <1% | 27 | $9K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,222 | $9K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 5,142 | $9K |
| 84305 | <1% | 36 | $8K | |
| 84450 | <1% | 519 | $8K | |
| 90688 | <1% | 717 | $8K | |
| 82140 | <1% | 48 | $8K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 285 | $8K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 30 | $7K |
| 86850 | <1% | 7,456 | $7K | |
| 95816 | <1% | 14 | $7K | |
| 76641 | <1% | 14 | $7K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,572 | $7K |
| L4386 | Walking boot, non-pneumatic, with or without joints, with or without interface material, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise | <1% | 12 | $7K |
| 84481 | <1% | 1,700 | $7K | |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 2,116 | $7K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 26 | $7K |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 1,644 | $7K |
| 87529 | <1% | 149 | $6K | |
| 80178 | <1% | 27 | $6K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 409 | $6K |
| 72050 | <1% | 13 | $6K | |
| L3807 | Wrist hand finger orthosis, without joint(s), prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise | <1% | 14 | $6K |
| 86708 | <1% | 1,340 | $6K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,606 | $6K |
| 82150 | <1% | 540 | $6K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,687 | $6K |
| 92587 | <1% | 1,272 | $6K | |
| 85730 | <1% | 9,385 | $5K | |
| Q0177 | Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,192 | $5K |
| 11721 | <1% | 14 | $5K | |
| J0588 | Injection, incobotulinumtoxin a, 1 unit | <1% | 83 | $5K |
| 97760 | <1% | 32 | $5K | |
| 92582 | <1% | 294 | $5K | |
| 70480 | <1% | 12 | $5K | |
| V5275 | Ear impression, each | <1% | 118 | $5K |
| 84460 | <1% | 530 | $5K | |
| 94010 | <1% | 14 | $5K | |
| 87507 | <1% | 18 | $5K | |
| 86160 | <1% | 115 | $5K | |
| 92592 | <1% | 24 | $4K | |
| 82805 | <1% | 2,026 | $4K | |
| 86901 | <1% | 7,947 | $4K | |
| 84075 | <1% | 12 | $4K | |
| 83002 | <1% | 220 | $4K | |
| 85014 | <1% | 201 | $4K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,793 | $4K |
| 70491 | <1% | 105 | $4K | |
| 87205 | <1% | 1,828 | $4K | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 1,486 | $3K |
| 11056 | <1% | 14 | $3K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 54,449 | $3K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 17 | $3K |
| 87185 | <1% | 12 | $3K | |
| 84100 | <1% | 1,415 | $3K | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 3,020 | $3K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,374 | $3K |
| 72070 | <1% | 12 | $3K | |
| 73100 | <1% | 16 | $3K | |
| 84550 | <1% | 78 | $3K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 322 | $3K |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 177 | $3K |
| 84132 | <1% | 158 | $3K | |
| 83721 | <1% | 7,785 | $3K | |
| 87088 | <1% | 2,276 | $3K | |
| 84134 | <1% | 13 | $2K | |
| 86304 | <1% | 12 | $2K | |
| 92136 | <1% | 100 | $2K | |
| 87493 | <1% | 42 | $2K | |
| 87075 | <1% | 1,510 | $2K | |
| 96040 | <1% | 37 | $2K | |
| 83921 | <1% | 36 | $2K | |
| 86376 | <1% | 172 | $2K | |
| 86787 | <1% | 12 | $2K | |
| 86360 | <1% | 45 | $2K | |
| 51741 | <1% | 13 | $2K | |
| 83789 | <1% | 679 | $2K | |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 55 | $2K |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 4,444 | $2K |
| 87147 | <1% | 6,371 | $2K | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 2,240 | $2K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 1,129 | $1K |
| 87186 | <1% | 9,393 | $1K | |
| 87045 | <1% | 129 | $1K | |
| 96376 | <1% | 4,842 | $1K | |
| 88312 | <1% | 81 | $1K | |
| 93226 | <1% | 367 | $1K | |
| 96416 | <1% | 14 | $1K | |
| 87902 | <1% | 172 | $1K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 710 | $1K |
| J2704 | Injection, propofol, 10 mg | <1% | 554 | $1K |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 249 | $1K |
| 84295 | <1% | 147 | $1K | |
| 92083 | <1% | 13 | $1K | |
| 76857 | <1% | 18 | $1K | |
| J2560 | Injection, phenobarbital sodium, up to 120 mg | <1% | 7,694 | $1K |
| 85018 | <1% | 177 | $1K | |
| 86225 | <1% | 52 | $784.00 | |
| 29130 | <1% | 14 | $784.00 | |
| 92235 | <1% | 12 | $784.00 | |
| 73060 | <1% | 13 | $784.00 | |
| 83550 | <1% | 11,234 | $695.75 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,397 | $635.46 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 100 | $592.00 |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 249 | $566.00 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 38 | $566.00 |
| 82977 | <1% | 13 | $566.00 | |
| 87046 | <1% | 139 | $566.00 | |
| 86696 | <1% | 416 | $548.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 126 | $548.00 |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 629 | $548.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 13 | $548.00 |
| 86769 | <1% | 559 | $228.00 | |
| G0008 | Administration of influenza virus vaccine | <1% | 1,946 | $119.00 |
| 90662 | <1% | 423 | $77.86 | |
| 80361 | 0% | 82 | $0.00 | |
| 84163 | 0% | 12 | $0.00 | |
| 81513 | 0% | 1,463 | $0.00 | |
| 0054A | 0% | 160 | $0.00 | |
| 87150 | 0% | 1,183 | $0.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 2,680 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 8,644 | $0.00 |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 0% | 153 | $0.00 |
| 86336 | 0% | 79 | $0.00 | |
| 91312 | 0% | 207 | $0.00 | |
| 93041 | 0% | 416 | $0.00 | |
| 82248 | 0% | 88 | $0.00 | |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 57 | $0.00 |
| 91322 | 0% | 74 | $0.00 | |
| 27096 | 0% | 15 | $0.00 | |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | 0% | 304 | $0.00 |
| J9263 | Injection, oxaliplatin, 0.5 mg | 0% | 219 | $0.00 |
| 96417 | 0% | 185 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 646 | $0.00 |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 0% | 498 | $0.00 |
| 87899 | 0% | 121 | $0.00 | |
| J1453 | Injection, fosaprepitant, 1 mg | 0% | 609 | $0.00 |
| 91300 | 0% | 341 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 533 | $0.00 |
| 0003A | 0% | 125 | $0.00 | |
| 82010 | 0% | 13 | $0.00 | |
| J7643 | Glycopyrrolate, inhalation solution, compounded product, administered through dme, unit dose form, per milligram | 0% | 56 | $0.00 |
| 94726 | 0% | 14 | $0.00 | |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | 0% | 33 | $0.00 |
| 91320 | 0% | 167 | $0.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 1,080 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 56 | $0.00 |
| 76937 | 0% | 111 | $0.00 | |
| 94729 | 0% | 63 | $0.00 | |
| 90670 | 0% | 37 | $0.00 | |
| 84165 | 0% | 13 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 73 | $0.00 |
| 0124A | 0% | 214 | $0.00 | |
| 87634 | 0% | 17 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 72 | $0.00 |
| S8100 | Holding chamber or spacer for use with an inhaler or nebulizer; without mask | 0% | 13 | $0.00 |
| 0004A | 0% | 117 | $0.00 | |
| 84155 | 0% | 12 | $0.00 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 22 | $0.00 |
| 0002A | 0% | 19 | $0.00 | |
| 96523 | 0% | 16 | $0.00 | |
| 90653 | 0% | 28 | $0.00 | |
| 86039 | 0% | 40 | $0.00 | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 0% | 36 | $0.00 |
| A0170 | Transportation ancillary: parking fees, tolls, other | 0% | 150 | $0.00 |
| 86923 | 0% | 12 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 92 | $0.00 |
| J0640 | Injection, leucovorin calcium, per 50 mg | 0% | 15 | $0.00 |
| 81425 | 0% | 12 | $0.00 | |
| 86235 | 0% | 12 | $0.00 | |
| J9190 | Injection, fluorouracil, 500 mg | 0% | 15 | $0.00 |
| J7121 | 5% dextrose in lactated ringers infusion, up to 1000 cc | 0% | 438 | $0.00 |
| 80320 | 0% | 6,775 | $0.00 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | 0% | 808 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 162 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 129 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 2,931 | $0.00 |
| 96415 | 0% | 776 | $0.00 | |
| 84480 | 0% | 32 | $0.00 | |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 421 | $0.00 |
| 87581 | 0% | 543 | $0.00 | |
| 83930 | 0% | 83 | $0.00 | |
| G0009 | Administration of pneumococcal vaccine | 0% | 154 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 549 | $0.00 |
| 36000 | 0% | 29 | $0.00 | |
| 0064A | 0% | 27 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 249 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 178 | $0.00 |
| 90694 | 0% | 205 | $0.00 | |
| 81511 | 0% | 39 | $0.00 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 97 | $0.00 |
| 36591 | 0% | 15 | $0.00 | |
| 82677 | 0% | 78 | $0.00 | |
| 91305 | 0% | 160 | $0.00 | |
| 90480 | 0% | 252 | $0.00 | |
| 86800 | 0% | 38 | $0.00 | |
| 82435 | 0% | 132 | $0.00 | |
| 70498 | 0% | 162 | $0.00 | |
| 82803 | 0% | 141 | $0.00 | |
| 91306 | 0% | 13 | $0.00 | |
| 90656 | 0% | 23 | $0.00 | |
| 93247 | 0% | 38 | $0.00 | |
| 0011A | 0% | 552 | $0.00 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 27 | $0.00 |
| G9035 | Oseltamivir phosphate, oral, brand, per 75 mg (for use in a medicare-approved demonstration project) | 0% | 13 | $0.00 |
| 93243 | 0% | 26 | $0.00 | |
| A0140 | Non-emergency transportation and air travel (private or commercial) intra or inter state | 0% | 169 | $0.00 |
| 84704 | 0% | 12 | $0.00 | |
| 0012A | 0% | 440 | $0.00 | |
| 0001A | 0% | 14 | $0.00 | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 0% | 42 | $0.00 |
| 95907 | 0% | 12 | $0.00 | |
| 80359 | 0% | 13 | $0.00 | |
| 91301 | 0% | 994 | $0.00 | |
| 90732 | 0% | 13 | $0.00 | |
| 82270 | 0% | 12 | $0.00 | |
| 70496 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSTRUBLE, GINAMARIE (DIRECTOR OF PATIENT ACCOUNTS)
| Provider | Location | Paid |
|---|---|---|
| Alaska Native Tribal Health Consortium | Anchorage, AK | $13.16M |
| Alaska Native Tribal Health Consortium | Anchorage, AK | $332K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.